Centiva Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Centiva Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,900	Closed	-$45.3K	–	2278
2024 Q4	$45.3K	Sell	14,900 -67,697	-82%	-$295K	﹤0.01%	1548
2024 Q3	$429K	Sell	82,597 -58,662	-42%	-$292K	0.01%	1356
2024 Q2	$363K	Buy	141,259 +126,259	+842%	+$431K	0.01%	1359
2024 Q1	$73.8K	Sell	15,000 -10,885	-42%	-$64.4K	﹤0.01%	1632
2023 Q4	$228K	Sell	25,885 -288,776	-92%	-$2.37M	0.01%	1353
2023 Q3	$3.61M	Buy	314,661 +274,661	+687%	+$5.28M	0.08%	225
2023 Q2	$1.01M	Buy	40,000 +13,800	+53%	+$430K	0.02%	565
2023 Q1	$844K	Buy	+26,200	New	+$817K	0.02%	659

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Centiva Capital's RVNC Position: Q1 2025 in Review

Centiva Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 14,900 shares — an estimated $45.3K sold.

Centiva Capital first reported a position in RVNC in Q1 2023 and held it in 8 quarters. The position peaked at $3.61M in Q3 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Centiva Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Centiva Capital sold 14,900 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $45.3K.
Centiva Capital first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 8 quarters.
Centiva Capital's Revance Therapeutics, Inc. position peaked at $3.61M in Q3 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.